Pear Therapeutics

2017: FDA permits marketing of mobile medical application for substance use disorder (by Pear Therapeutics)

Today, the U.S. Food and Drug Administration permitted marketing of the first mobile medical application to help treat substance use disorders (SUD).

The Reset device is a mobile medical application system containing a patient application and clinician dashboard. The device delivers cognitive behavioral therapy to patients to teach the user skills that aid in the treatment of SUD and are intended to increase abstinence from substance abuse and increase retention in outpatient therapy programs. The system is intended to be used in conjunction with outpatient therapy and in addition to a contingency management system, a widely-used program for treating SUD that uses a series of incentives to reward patients for adherence to their treatment program.

The FDA reviewed data from a multi-site, unblinded 12-week clinical trial of 399 patients.

2016: Pear Therapeutics Closes $20 Million Financing - Pear Therapeutics

Pear Therapeutics (PEAR), the creator of prescription digital therapies called eFormulationsTM, announced today that it has successfully closed on a $20M equity financing. 5AM Ventures, Arboretum Ventures, and JAZZ Venture Partners led the round

PEAR is developing digital therapies, called eFormulations, to treat disease and enhance the efficacy of pharmaceuticals.

“From mobile applications, to virtual reality, to predictive analytics, PEAR’s digital therapeutics platform directly boosts medication efficacy, well beyond enhanced compliance.” said Zack Lynch, General Partner at JAZZ Venture Partners.

In addition to PEAR’s addiction products, the Company is launching on its platform a pipeline of eFormulations for treating many of the disorders of the brain. The Company’s product targeting schizophrenia has already demonstrated patient usability and clinical efficacy in combination with multiple medications, and is currently being examined in multiple large-scale clinical trials involving patients with schizophrenia, schizoaffective disorder, and bipolar disorder. PEAR has also developed products enhancing medications for treating chronic pain, post-traumatic stress disorder (PTSD), general anxiety disorder (GAD), major depressive disorder (MDD), and insomnia.